Teva's early Copaxone-switching success turns analysts into believers

Save

Early progress doesn't always equal long-term success. But at least in the case of Teva Pharmaceutical Industries–which is firing on all cylinders to convert patients to a new, long-acting version of Copaxone–early results have some analysts thinking the Israeli company may deliver on its promise to switch 30% to 50% of patients.